TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01820026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: second line therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Second line therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azithromycin
Description: Second line therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: Second line therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Standard antibiotic therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Standard therapy
Study: NCT03312530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arm.
Study: NCT02829268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dantrolene sodium
Description: The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dantrolene sodium
Description: The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical \& medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires.
Study: NCT01881321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention
Description: 20-40 minute contraceptive counseling session based on the principles of motivational interviewing
Study: NCT03622658

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Namilumab
Description: Namilumab solution for subcutaneous injection
Study: NCT01412580

Intervention type: OTHER
Intervention: observational follow-up
Description: observational follow-up
Study: NCT02654912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Focal Drug Administration
Description: This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
Study: NCT01718938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: velusetrag dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01157091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study: NCT02301676

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Korean version of telephone interview for cognitive status
Description: The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
Study: NCT04500470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen + INH
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table 900 mg vaginal isonicotinic acid hydrazide by the patient 12 hours before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketoprofen + placebo
Description: patients will have of oral Ketoprofen 60 minutes before the procedure plus 3 table placebo by the patient 12 hours before the procedure
Study: NCT01059903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Description: Rotigotine 4.5 mg/10 cm\^2 patch applied for 24 hours
Study: NCT03382756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: A diet consisting of more than 900kcal and 35% of fat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: A diet consisting of more than 900kcal and 35% of fat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-337
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-337
Description: Test Drug
Study: NCT02231645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN DBS
Description: The DBS device is turned on and off by the physician.
Study: NCT02146430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg tablet for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin 150 mg capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet (matching DS-5565) for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS-5565) for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet (matching DS-5565) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule (matching pregabalin) for oral administration
Study: NCT00854308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib HCl
Description: Erlotinib 150 mg oral dose once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib HCl
Description: Erlotinib 150 mg oral dose once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetMAb
Description: MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (0.9 % saline)
Description: Placebo Intravenous infusion every 3 weeks.
Study: NCT02886468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin ultrasound
Study: NCT02931318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nevsehir
Description: The data of the study were collected with the questionnaire
Study: NCT01130025

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innohep®
Description: Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
Study: NCT03613259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo fluorothymidine F-18 PET
Study: NCT00803803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Concentration
Description: Varying concentration 0.5 to 8%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine Frequency
Description: 1 to 4 times daily
Study: NCT01458405

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CAP-1002 Allogeneic Cardiosphere-Derived Cells
Description: Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single, blinded, intracoronary infusion of a placebo solution
Study: NCT01218165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic drink
Description: This group receives a probiotic drink daily for 6 week.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: without intervention
Study: NCT01790568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Study: NCT03805438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroprocaine Hcl 3% Inj
Description: Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine - Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml.
Study: NCT00799656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration 200mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ataciguat (HMR1766)
Description: oral administration 200mg once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration once daily for 28 days
Study: NCT03025594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonyautoxins
Description: Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chirocaine ketorolac epinephrine
Description: Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
Study: NCT01007500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
Study: NCT00994253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
Study: NCT02359331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: H. pylori culture and antimicrobial susceptibility testing
Description: This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 days empirical bismuth quadruple therapy (Proton pump inhibitor)
Description: Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tripotassium dicitrate bismuthate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7 days tailored therapy Proton Pump Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study: NCT01469364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aztreonam Lysine for Inhalation (AZLI)
Description: The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Status Post Lung Transplant
Description: Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
Study: NCT04817709

Intervention type: OTHER
Intervention: Educational Intervention
Description: Review workbook

Intervention type: OTHER
Intervention: Usual Care
Description: Receive educational materials

Intervention type: OTHER
Intervention: Media Intervention
Description: Watch video

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02292745

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiotherapy
Study: NCT00607230

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG
Description: BCG vaccination at 0 and 4 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline vaccination at 0 and 4 weeks
Study: NCT01934621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Study: NCT03165058

Intervention type: DIAGNOSTIC_TEST
Intervention: mucosal impedance (MI) testing
Description: During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.

Intervention type: DIAGNOSTIC_TEST
Intervention: mucosal impedance (MI) testing
Description: During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
Study: NCT03815838

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET imaging
Description: Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
Study: NCT02652026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Description: Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Prophylaxis
Description: Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Prophylaxis
Description: Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)